微电生理2025年业绩快报：营收增长12.43%，净利润微降1.76%

Group 1: Financial Performance - The company reported a total revenue of 464.53 million yuan for 2025, representing a year-on-year increase of 12.43% [1] - The net profit attributable to the parent company was 51.15 million yuan, showing a decline of 1.76% compared to the previous year [1] - The net profit excluding non-recurring gains and losses was 23.66 million yuan, significantly increasing compared to 2024 [1] - The growth in performance was primarily driven by overseas revenue, which increased by over 40% and accounted for more than 30% of total revenue [1] - In domestic operations, the usage of pressure monitoring radiofrequency ablation catheters increased by over 70%, contributing to the upgrade of high-end procedures [1] Group 2: Recent Events - The company announced on February 10, 2026, that its magnetic navigation ablation catheter and star-shaped high-density mapping catheter received EU Medical Device Regulation (MDR) certification, facilitating entry into the European market and enhancing its overseas technology matrix [2] - On February 11, 2026, the company disclosed that approximately 346 million shares of restricted stock will be released for trading on March 2, 2026, representing 73.47% of the total share capital, which may exert liquidity pressure on the stock price [2] Group 3: Stock Performance - The stock price experienced fluctuations, closing at 23.50 yuan on February 12, 2026, with a 7-day price change of 0.95% and a volatility of 4.64% [3] - The stock dropped by 1.43% on February 11, 2026, the day the earnings report was disclosed, with a trading volume of 58.88 million yuan [3] - On February 12, 2026, the net outflow of funds from major investors was 5.11 million yuan, while retail investor activity remained high [3] - The medical device sector declined by 0.83% during the same period, underperforming the broader market [3]